Trials / Unknown
UnknownNCT03007446
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Prospective，Single-center，Single-arm，Open-label exploratory clinical trial evaluating the efficacy and safety of Conversion Surgery for Apatinib plus SOX for patients with unresectable gastric cancer.
Detailed description
Gastric cancer is the second most common cause of cancer-related deaths worldwide, and surgical resection during the early stage has improved treatment outcomes.However, many patients are diagnosed with unresectable advanced or metastatic stage disease losing the radical surgery opportunity. Systemic chemotherapy is the leading treatment that prolongs survival times for such patients. Approximate 20 patients with unresectable gastric cancer will be enrolled in this study,the investigators will evaluate the efficacy and security of Apatinib + SOX(oxaliplatin+S-1) for unresectable gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib :A starting dose of apatinib was administered 500 mg daily |
| DRUG | Oxaliplatin | Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle |
| DRUG | S-1 | S-1:40mg，bid，d1-14，po，in a 21 day cycle. |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
- First posted
- 2017-01-02
- Last updated
- 2017-09-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03007446. Inclusion in this directory is not an endorsement.